Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asundexian after acute non-cardioembolic ischemic stroke or high-risk TIA
NL-OMON51380Phase 3Recruiting
- Sponsor
- Bayer
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke and transient ischaemic attack (TIA) comparing Asundexian + standard antiplatelet therapy with Placebo + standard antiplatelet therapy (2 arms). Primary endpoints: Ischemic stroke and ISTH major bleeding. Started Mar 2023; status: recruiting.
02
Drugs
asundexian
03
Conditions
ischemic stroketransient ischaemic attack (TIA)
Beyond the preview
Go deeper on NL-OMON51380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51380.